Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2019 | Real world data for CD19 CAR-T in lymphoma patients in England

Claire Roddie • 7 Dec 2019
ASH 2019
B-Cell Lymphoma Diffuse Large B-Cell Lymphoma Lymphoma CAR-T

Claire Roddie, MD, PhD, University College London, London, United Kingdom, discusses real world data for relapsed/refractory high-grade lymphoma patients treated with CD19 CAR-T in England. This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.

More from Claire Roddie

1:28
Insights into the UCL CAR T program
Claire Roddie • 3 Jun 2023
Updates in ALL
Bijal Shah et al. • 14 Apr 2023
3:38
Mechanisms of resistance to CAR-T in ALL: T-cell fitness, antigen loss and immunological rejection
Claire Roddie • 3 Jun 2023
4:45
Safety and efficacy of obe-cel in R/R adult B-ALL: results of the pivotal FELIX study
Claire Roddie • 3 Jun 2023

Related Videos

3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
2:11
The role of CAR-T therapy for lymphoma in 2024: expert session highlights
Sridhar Chaganti • 16 Apr 2024
1:32
Promising novel immunotherapeutic approaches in lymphoma
Gloria Iacoboni • 15 Apr 2024
3:03
AlloSCT outcomes after immunotherapy vs chemotherapy in patients with R/R NHL: a retrospective study
Jacopo Mariotti • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals